Search 

Charnwood Molecular is an integrated drug discovery provider with a 25-year track record of delivery to our clients worldwide, many of whom are emerging pharmaceutical companies.

We believe in bringing together the right experts, technologies, capabilities, and passion, to support customer drug discovery projects and deliver potent, selective, and drug-like candidates.  Our experienced project scientists (medicinal chemistry, biology, computational chemistry, ADME/PK and process chemistry) understand the drug discovery process, the importance of physicochemical properties, the interrogation of biological data and generation of SAR, with expertise in all major disease areas and targets.

Since our inception in 1998 we have successfully supported hundreds of life science groups globally, from academic groups and virtual start-ups to established biotechnology and pharmaceutical companies. We place great emphasis on open collaboration in our client relationships. What makes Charnwood Molecular unique is our unwavering passion for the truly ground-breaking science we facilitate and the trusting relationships we build.

We are a leading provider of outsourced commercial, medical and recruitment services to pharmaceutical, biotech and healthcare companies. Working exclusively in the United Kingdom, we have brand strategy, implementation, and recruitment experience from numerous launches across prescription medicines, medical devices, and medical software. We provide a UK launch solution for pharmaceutical, biotech and medtech companies, that is an alternative to out-licensing and traditional distribution arrangements.

Curileum is a biotechnology company in London that focuses on
discovering and developing novel therapeutics to intervene early
in the development of severe GI diseases. With a dynamic team of
scientists committed to translating our science to game-changing
therapies, we have discovered and delivered two first-in-class
preclinical therapeutic candidates and a compelling novel drug
target.
ULI-015 a small molecule to reduce polyp formation and progression
to bowel cancer.
ATZ stem cell therapy to repair an incurable condition in Crohn’s
disease patients.
CSR-1 a soluble regulator in Crohn’s patients that drives chronic gut
inflammation.
Curileum is seeking co-development and licensing partners for its
two de-risked, first-in-class preclinical therapeutic candidates and a
collaboration partner to develop a small molecule antagonist to our
novel drug target driving chronic gut inflammation.
Learn more at curileum.com